These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 23193945)

  • 1. Ultrasonographic markers and preoperative CA-125 to distinguish between borderline ovarian tumors and stage I ovarian cancer.
    Zacharakis D; Thomakos N; Biliatis I; Rodolakis A; Simou M; Daskalakis G; Bamias A; Antsaklis A
    Acta Obstet Gynecol Scand; 2013 Mar; 92(3):285-92. PubMed ID: 23193945
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Elevated Preoperative CA125 or CA19-9 in Borderline Ovarian Tumors: Could It Be Suggestive of Advanced Stage or a Poor Prognosis?
    Song T; Lee DH; Jung YW; Yun BS; Seong SJ; Choi CH; Lee JW; Bae DS; Kim BG
    Gynecol Obstet Invest; 2018; 83(1):45-51. PubMed ID: 28571024
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is CA-125 an additional help to radiologic findings for differentiation borderline ovarian tumor from stage I carcinoma?
    Lee EJ; Kim SH; Kim YH; Lee HJ
    Acta Radiol; 2011 May; 52(4):458-62. PubMed ID: 21498310
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differentiating between borderline and invasive malignancies in ovarian tumors using a multivariate logistic regression model.
    Chen J; Chang C; Huang HC; Chung YC; Huang HJ; Liou WS; Chiang AJ; Teng NN
    Taiwan J Obstet Gynecol; 2015 Aug; 54(4):398-402. PubMed ID: 26384058
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum human epididymal protein 4 (HE4) as biomarker for the differentiation between epithelial ovarian cancer and ovarian metastases of gastrointestinal origin.
    Stiekema A; Boldingh QJ; Korse CM; van der Noort V; Boot H; van Driel WJ; Kenter GG; Lok CA
    Gynecol Oncol; 2015 Mar; 136(3):562-6. PubMed ID: 25560808
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasma fibrinogen levels in patients with benign and malignant ovarian tumors.
    Hefler-Frischmuth K; Lafleur J; Hefler L; Polterauer S; Seebacher V; Reinthaller A; Grimm C
    Gynecol Oncol; 2015 Mar; 136(3):567-70. PubMed ID: 25576886
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pre-operative evaluation of ovarian tumors by risk of malignancy index, CA125 and ultrasound.
    Arun-Muthuvel V; Jaya V
    Asian Pac J Cancer Prev; 2014; 15(6):2929-32. PubMed ID: 24761927
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma immune analytes in patients with epithelial ovarian cancer.
    Block MS; Maurer MJ; Goergen K; Kalli KR; Erskine CL; Behrens MD; Oberg AL; Knutson KL
    Cytokine; 2015 May; 73(1):108-13. PubMed ID: 25743245
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A predictive model combining human epididymal protein 4 and radiologic features for the diagnosis of ovarian cancer.
    Stiekema A; Lok CA; Kenter GG; van Driel WJ; Vincent AD; Korse CM
    Gynecol Oncol; 2014 Mar; 132(3):573-7. PubMed ID: 24418200
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of tumor markers and clinicopathological features in serous and mucinous borderline ovarian tumors.
    Alanbay I; Aktürk E; Coksuer H; Ercan CM; Karaşahin E; Dede M; Yenen MC; Ozan H; Dilek S
    Eur J Gynaecol Oncol; 2012; 33(1):25-30. PubMed ID: 22439401
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diagnostic performance of the biomarkers HE4 and CA125 in type I and type II epithelial ovarian cancer.
    Kristjansdottir B; Levan K; Partheen K; Sundfeldt K
    Gynecol Oncol; 2013 Oct; 131(1):52-8. PubMed ID: 23891789
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Elevated plasma fibrinogen levels and prognosis of epithelial ovarian cancer: a cohort study and meta-analysis.
    Luo Y; Kim HS; Kim M; Lee M; Song YS
    J Gynecol Oncol; 2017 May; 28(3):e36. PubMed ID: 28382799
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of serum CA-125 levels and CA-125 tissue expression positivity in the prediction of the recurrence of stage III and IV epithelial ovarian tumors (CA-125 levels and tissue CA-125 in ovarian tumors).
    Gundogdu F; Soylu F; Erkan L; Tatli O; Mavi S; Yavuzcan A
    Arch Gynecol Obstet; 2011 Jun; 283(6):1397-402. PubMed ID: 20645105
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clinical characteristics of borderline ovarian tumors and stage I epithelial ovarian cancer: an analysis of 143 cases].
    Zhao Y; Wang Y; Shen Dh; Song Rn; Xu Q; Li Y; Cui H; Tang J; Wei Lh
    Beijing Da Xue Xue Bao Yi Xue Ban; 2011 Feb; 43(1):123-8. PubMed ID: 21321635
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnostic extended usefulness of RMI: comparison of four risk of malignancy index in preoperative differentiation of borderline ovarian tumors and benign ovarian tumors.
    Zhang S; Yu S; Hou W; Li X; Ning C; Wu Y; Zhang F; Jiao YF; Lee LTO; Sun L
    J Ovarian Res; 2019 Sep; 12(1):87. PubMed ID: 31526390
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The serum CA-125 concentration data assists in evaluating CT imaging information when used to differentiate borderline ovarian tumor from malignant epithelial ovarian tumors.
    Shin JE; Choi HJ; Kim MH; Cho KS
    Korean J Radiol; 2011; 12(4):456-62. PubMed ID: 21852906
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum HE4 levels combined with CE CT imaging improve the management of monitoring women affected by epithelial ovarian cancer.
    Manganaro L; Michienzi S; Vinci V; Falzarano R; Saldari M; Granato T; Viggiani V; Frati L; Anastasi E
    Oncol Rep; 2013 Nov; 30(5):2481-7. PubMed ID: 23970060
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preoperative measurement of serum C-reactive protein: is it useful in the differential diagnosis of adnexal masses?
    Yoshida A; Derchain SF; Pitta DR; Crozatti N; Andrade LALA; da Silva RF; Sarian LO
    Int J Biol Markers; 2017 Mar; 32(1):e83-e89. PubMed ID: 27516000
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical value of human epididymis protein 4 and the Risk of Ovarian Malignancy Algorithm in differentiating borderline pelvic tumors from epithelial ovarian cancer in early stages.
    Kotowicz B; Fuksiewicz M; Sobiczewski P; Spiewankiewicz B; Jonska-Gmyrek J; Skrzypczak M; Kowalska M
    Eur J Obstet Gynecol Reprod Biol; 2015 Nov; 194():141-6. PubMed ID: 26398337
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Biomarker Panel Increases the Diagnostic Performance for Epithelial Ovarian Cancer Type I and II in Young Women.
    Leandersson P; Kalapotharakos G; Henic E; Borgfeldt H; Petzold M; Høyer-Hansen G; Borgfeldt C
    Anticancer Res; 2016 Mar; 36(3):957-65. PubMed ID: 26976984
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.